Quick Answer
CNS Pharmaceuticals, Inc. reported Net Income of -$15.85 million for fiscal year 2025.
CNS Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$15.85M -6.7% |
-$14.86M +21.2% |
-$18.85M -23.4% |
-$15.27M -5.4% |
-$14.50M -53.3% |
-$9.46M -143.9% |
| Diluted EPS | -$35.75 +92.3% |
-$466.89 +96.3% |
-$12509.11 -111389.4% |
-$11.22 +32.0% |
-$16.50 | — |
| Total Assets | $8.62M -0.9% |
$8.70M +411.6% |
$1.70M -87.0% |
$13.05M +49.1% |
$8.76M -44.8% |
$15.85M +100.4% |
| Cash and Equivalents | $7.20M +11.4% |
$6.46M +1077.5% |
$548.7K -94.5% |
$10.06M +100.9% |
$5.00M -64.4% |
$14.04M +93.9% |
| Stockholders Equity | $4.52M -26.8% |
$6.18M +239.4% |
-$4.43M -154.5% |
$8.13M +32.0% |
$6.16M -55.8% |
$13.95M +83.5% |
| R&D Expense | $9.77M +5.2% |
$9.29M -34.1% |
$14.10M +51.6% |
$9.30M -5.2% |
$9.81M +93.7% |
$5.06M +173.0% |
| Operating Income | -$15.99M -7.3% |
-$14.90M +21.0% |
-$18.87M -23.6% |
-$15.27M -5.4% |
-$14.49M -53.2% |
-$9.45M -146.7% |
| Shares Outstanding | 632,516 +437.0% |
117,796 +4638.4% |
2,486 -99.8% |
1.62M +70.4% |
949,052 -96.0% |
23.86M +45.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$3.22M | +42.6% | -35.5% |
| Diluted EPS | September 30, 2025 | -$5.76 | +96.2% | +10.3% |
| Total Assets | September 30, 2025 | $11.87M | +60.2% | -18.2% |
| Cash and Equivalents | September 30, 2025 | $9.86M | +41.5% | -18.7% |
| Stockholders Equity | September 30, 2025 | $9.91M | +195.6% | -24.5% |
| R&D Expense | September 30, 2025 | $2.20M | -48.2% | +88.2% |
| Operating Income | September 30, 2025 | -$3.25M | +42.2% | -35.0% |
| Shares Outstanding | September 30, 2025 | 574,580 | -98.3% | +13.9% |
- CNS Pharmaceuticals, Inc. reported Net Income of -$15.85 million for fiscal year 2025.
- CNS Pharmaceuticals, Inc. showed a decrease of -6.7% in Net Income compared to the prior fiscal year.
- CNS Pharmaceuticals, Inc. reported Diluted EPS of $35.75 per share (loss) for fiscal year 2025.
- CNS Pharmaceuticals, Inc. showed an increase of +92.3% in Diluted EPS compared to the prior fiscal year.
- CNS Pharmaceuticals, Inc. reported Total Assets of $8.62 million for fiscal year 2025.
- CNS Pharmaceuticals, Inc. showed a decrease of -0.9% in Total Assets compared to the prior fiscal year.
- CNS Pharmaceuticals, Inc. reported Cash and Equivalents of $7.20 million for fiscal year 2025.
- CNS Pharmaceuticals, Inc. showed an increase of +11.4% in Cash and Equivalents compared to the prior fiscal year.
- CNS Pharmaceuticals, Inc. reported Stockholders Equity of $4.52 million for fiscal year 2025.
- CNS Pharmaceuticals, Inc. showed a decrease of -26.8% in Stockholders Equity compared to the prior fiscal year.
- CNS Pharmaceuticals, Inc. reported R&D Expense of $9.77 million for fiscal year 2025.
- CNS Pharmaceuticals, Inc. showed an increase of +5.2% in R&D Expense compared to the prior fiscal year.
- CNS Pharmaceuticals, Inc. reported Operating Income of -$15.99 million for fiscal year 2025.
- CNS Pharmaceuticals, Inc. showed a decrease of -7.3% in Operating Income compared to the prior fiscal year.
- CNS Pharmaceuticals, Inc. reported Shares Outstanding of 632.5 thousand shares for fiscal year 2025.
- CNS Pharmaceuticals, Inc. showed an increase of +437.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: